Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

Summary

This study tests whether adding certain genetic factors to the process of picking a stem cell donor can decrease the chances that the patient's leukemia will come back after bone marrow transplantation. Stem cell donors are "matched" based on genes called human leukocyte antigens (HLA).

Currently, donors are selected largely on the basis of HLA gene typing alone. There is published data to show that donors with specific other genes called killer immunoglobulin-like receptors (KIR) may protect AML patients from having their leukemia return after a transplant. In this study, the best HLA matched donors will be tested for the KIR genes. If there is more than 1 donor available, a recommendation will be provided to study doctors as to which donors have potentially favorable KIR genes. The study doctors may or may not choose to use this donor for transplant or not based on his/her own judgment. Transplant care will not change otherwise as a result of this study.

This study is being done to demonstrate that AML patients who have donors with specific KIR and HLA genes will have a better outcome following transplant.

Conditions

• Leukemia

Interventions

GENETIC

KIR genotyping

GENETIC

HLA genotyping

Sponsors & Collaborators

• Center for International Blood and Marrow Transplant Research

  collaborator NETWORK

• Hackensack Meridian Health

  collaborator OTHER

• H. Lee Moffitt Cancer Center and Research Institute

  collaborator OTHER

• M.D. Anderson Cancer Center

  collaborator OTHER

• Dana-Farber Cancer Institute

  collaborator OTHER

• University of Washington

  collaborator OTHER

• Mayo Clinic

  collaborator OTHER

• Duke University

  collaborator OTHER

• Memorial Sloan Kettering Cancer Center

  lead OTHER

Principal Investigators

• Katherine Hsu, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Model

PARALLEL

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-05-31

Primary Completion

2026-05-31

Completion

2026-05-31

Countries

• United States

Study Locations